Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy.
Zev A WainbergArun S SinghGottfried E KonecnyKelly E McCannJ Randolph HechtJonathan Wade GoldmanBartosz ChmielowskiRichard S FinnNeil A O'BrienErika von EuwMegan M PriceDiego MartinezLisa YonemotoMeghan BrennanJohn A GlaspyDennis J SlamonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These results show that TAL with low-dose TMZ or IRI is reasonably well-tolerated and demonstrates clinical activity in a wide range of cancers. Randomized trials of TAL with or without low dose chemotherapy are ongoing in small cell lung cancer (SCLC) and ovarian cancer.